Managing Director, Clarus
Scott has over 15 years of operating and investment experience in the pharmaceutical industry. He has been involved in multiple Clarus investments spanning both therapeutics and medtech. Prior to joining Clarus in 2005, Scott was Director, Business Development at TransForm Pharmaceuticals, until it was acquired by Johnson & Johnson. At TransForm he was responsible for business development, corporate development and legal activities. Before TransForm, Scott practiced for several years as an M&A attorney at Davis Polk & Wardwell, where he represented numerous private equity, pharma and technology clients. Before that, Scott was a law clerk for a senior judge at the Supreme Court of Canada. He currently serves on the Boards of Edev, VBI Vaccines (Nasdaq: VBIV) and ESSA Pharmaceuticals (Nasdaq: EPIX) and has previously been a Board member or observer of TyRx (acquired by Medtronic), Oxford Immunotec (Nasdaq: OXFD), Catabasis Pharmaceuticals (Nasdaq: CATB), Link Medicine (acquired by AstraZeneca) and Biolex Therapeutics.
Find more info about Scott here.